|
Petercam plays an active
role in
providing companies and shareholders with the right means to
finance their expansion plans and/or
realise exits through IPO's, follow-on offerings and
private placements.
Petercam's longstanding involvement in
financial markets and the outstanding
reputation of its sell-side
research provides
customers with a unique partner
to successfully realise their capital markets projects.
Our permanent contacts with institutional
investors and access to high net worth individuals are decisive
factors in facilitating the access of medium-sized and large
corporations to capital markets.
Petercam has participated in about one third of the IPO's
of Belgian companies over the last 15 years and has been a
leading member of placing syndicates in many follow-on public
offerings in recent years.
The realisation of private placements for unlisted companies,
whether family-owned or VC-backed, completes the range of services
that assist customers through the various steps of their development.
SELECTED TRANSACTIONS :
 |
|
Tigenix is a biomedical company that focuses on regenerative medicine to develop durable treatments for damaged and osteoarthritic joints. ChondroCelect, the company’s lead product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, over clinical development to central European registration as a medicinal product.
|
|
Petercam acted as Joint Bookrunner for the private placement. The placing was realised through an accelerated bookbuild offering with Belgian and international institutional and professional investors. |
|
 |
|
ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the nonsurgical treatment of back of the eye diseases.
|
|
Petercam acted as Sole Global Co-ordinator and Joint Bookrunner for the €42 million (9,99% of the outstanding shares) private placement. A substantial demand was generated through an accelerated book build offering with a large number of high quality Belgian and international institutional and professional investors. |
|
 |
|
WDP, the leading Belgian real estate investment company in logistical and semi-industrial property, announced in June 2009 a rights offering of 1 new for 3 existing shares at a subscription price representing a discount of 11,4%. The use of proceeds was twofold: to finance future portfolio growth and to decrease its leverage, mainly through the reduction of a short term debt position in commercial paper.
|
|
Petercam as Joint Lead Manager and Bookrunner structured the offering, organized an extensive roadshow and successfully marketed the new shares. 94,1% of the rights were already exercised after the first phase of the offering. |
|
 |
|
Cofinimmo, the leading Belgian real estate investment company, owned 330.000 treasury shares (c.3% of ordinary share capital) following a number of acquisitions and mergers. The treasury shares were successfully placed in the market on 9 June 2009.
|
|
Petercam as Sole Bookrunner for the private placement successfully placed the shares to local and international institutional investors through an accelerated book-building. |
|
 |
|
Cardio3
Biosciences is a Belgian bio-medical company focused
on cellular therapy for heart tissues.
|
|
Petercam
assisted the Company in its second financing
round, which was closed at the end of 2008. |
|
 |
|
ThromboGenics
is a Belgium-based biopharmaceutical company focused
on the development of therapeutics for conditions related
to the vascular system. The Company is focused on developing
new medicines to treat visual disorders, cardiovascular
diseases and cancer. Recently, a group of investors
united themselves and took an 11% stake in ThromboGenics
with the intention to form a stable reference shareholder
base.
|
|
Petercam
searched for interested investors and coordinated
the set-up of the shareholder group. |
|
 |
|
4
Energy Invest, a clean energy producer, realized a capital
increase through an initial public offering and listing
on NYSE Euronext Brussels. Through this transaction the
company was able to secure equity financing for its important
investment program, both current as well as planned pipeline.
|
|
Petercam
acted as co-lead manager in the offering syndicate.
Next to its role in the placement, Petercam continued
to offer independent sell side research on the
company. The IPO of 4 Energy Invest was the only
equity offering on the first market of NYSE-Euronext
Brussels in 2008. |
|
 |
|
Punch
Graphix, a company that provides imaging and printing
solutions for the global graphics industry was looking
to increase its capital.
|
|
As
lead manager Petercam realized a private placement
of EUR 60 million of which EUR 30 million was
subscribed by the reference shareholder of Punch
Graphix. A substantial demand was generated through
a book building with a large number of high quality
international institutional investors. |
|
 |
|
Pinguin
is a deep-frozen vegetable specialist with a product
offering ranging from freshly frozen and cooled basic
vegetables to deep-frozen culinary, ready-made meals,
soups and sauces. In 2007, the Company acquired Lutosa,
a producer of potato-based products, and decided to increase
its capital through a rights issue.
|
|
Petercam
acted as a joint lead manager in the EUR 46m
offering. 100% of the offered shares were successfully
placed. |
|
 |
|
Nyrstar
is the world's largest zinc metal producer and
one of the world’s largest producers of primary
lead. The Company produces other valuable by-products
including silver, sulphuric acid, indium, copper and
gold. The Company was created in 2007 by combining the
zinc and lead smelting and alloying operations of Zinifex
(an Australian mining company) and Umicore (a Belgian
materials technology company). In October 2007, the Company
was listed on NYSE Euronext Brussels.
|
|
Petercam
acted as co-manager in the syndicate that managed
the initial public offering (IPO). |
|
 |
|
TiGenix
is a late-stage biomedical company focused on regenerative
treatments for damaged and osteoarthritic joints with
a Product with s uccessful Phase III data in cartilage
repair and other innovative treatments in pipeline.
|
|
The
Tigenix IPO was more than 4 times oversubscribed
albeit in difficult market circumstances. As
a co-lead manager Petercam provided a substantial
contribution to the selling group, both in the
institutional and in the retail tranches. Petercam
was eventually allotted close to 20% of the
total offering. |
|
 |
|
Devgen
is an innovator in biotechnology focused on discovering,
developing and commercializing a a novel generation
of biotech products in crop protection and novel therapeutic
concepts and preclinical drug candidates for treatment
of metabolic disease and inflammation.
|
|
As
co-lead manager Petercam provided a substantial
contribution to the private placement of EUR
31 million of new shares and EUR 49 million
of existing shares. A demand of more than 3
times the aggregate offer was generated through
an accelerated book-building with a large number
of high quality Belgian and international institutional
investors. |
|
 |
|
Solvac,
a listed holding company and Solvay's reference
shareholder with 27% of the capital before the transaction,
was looking to increase its participation in Solvay
above the 30% threshold foreseen in the upcoming new
legislation on takeover bids.
|
|
Petercam
as financial advisor to Solvac, tested a number
of scenarios and eventually assisted Solvac
in the acquisition of 3% in Solvay on the stock
market for EUR 245 million and in the realisation
of a EUR 180 million rights offering aimed at
partly refinancing the share purchases. 100%
of the rights offering were subscribed. |
|
 |
|
Metris
designs, develops and markets a unique range of 3D hardware
and software inspection systems for the automotive and
aerospace sectors. The company offers world-class metrology
solutions for both design and manufacturing communities.
Metris' headquarters are in Leuven (Belgium)
with additional production and development centers in
UK, U, China, Russia, India and Bulgaria.
|
|
As
a co-lead manager Petercam provided a substantial
contribution to the selling group, both in the
institutional and in the retail tranches. |
|
 |
|
The
Claeys family, one of the two founding families behind
the Kinepolis group, sold their 25% stake to institutional
investors in Europe.
|
|
Petercam
advised the Claeys family and organized the placement
of the shares in an accelerated book building. |
|
 |
|
End
June 2006, Partners in Lighting and WDP announced the
sale of two PLI buildings to WDP for a combined consideration
of nearly 37mEUR of which 29,4 mEUR to be paid in WDP
shares. PLI mandated Petercam to place the newly issued
WDP shares, representing 8,2% of capital the day following
their payment to PLI.
|
|
Petercam
generated a total demand of about 1,9 million
shares, i.e. 2,6 times the number of shares
initially offered, via an accelerated book-building
between 8h30 and midday. Petercam placed the
shares at a discount of 2% to around 22 local
and international institutional investors. |
|
 |
|
The
family shareholders, owning 35% of of the Deceuninck
Group, were looking for a financial partner for half
of their participation in view of the stabilisation
of the shareholding. The family preferred a solid, financial
partner with a strong industrial and Belgian embedment.
|
|
Petercam
as a joint financial advisor to the family shareholders
invited a limited number of financial parties,
of which several showed a clear interest.
Finally, Sofina was selected because of its acquaintance
with the sector and its outstanding reputation.
The transaction was kept strictly confidential
up to its announcement. The agreed price amounted
to EUR 23 per share, valuing the participation
at EUR 87 million. |
|
 |
|
Petercam
as joint lead manager successfully placed EUR 50 million
of new shares (representing 9,9% of capital) via accelerated
book building at a discount of merely 2,9% to the prior
closing price.
|
|
In
less than 2 hours a demand of almost 4 times
the offer was generated with 52 local and international
institutional investors. |
|
|
